Scilit logo
  • Rankings
  • Search Publications
    Cited-by Search
  • Sources
  • Publishers
  • Scholars
    Top Cited Scholars
  • Organizations
  • Scilit
    About Us
    Advisory Board
    Data Sources
    Career
    Support / Contact
    User Guide
    Publisher User
    Search Function
    Rankings Function
    API Resource
    Scilit Knowledge
    Metrics
    Scilit Recognitions
    Publications Classification
    Media
    News
    Blog
Register
  1. Home
  2. Publications
  3. Supplementary Figure S4 from Gemcitabine plus Nivolumab with Carboplatin or Oxaliplatin in Cisplatin-Ineligible Patients with Metastatic Urothelial Carcinoma: A Randomized Phase II Trial
  1. Home
  2. Publications
  3. Supplementary Figure S4 from Gemcitabine plus Nivolumab with Carboplatin or Oxaliplatin in Cisplatin-Ineligible Patients with Metastatic Urothelial Carcinoma: A Randomized Phase II Trial

Supplementary Figure S4 from Gemcitabine plus Nivolumab with Carboplatin or Oxaliplatin in Cisplatin-Ineligible Patients with Metastatic Urothelial Carcinoma: A Randomized Phase II Trial

Authors:
  • ZLZiao Li
    Ziao Li
  • SISudeh Izadmehr
    Sudeh Izadmehr
  • JHJeannie Hoffman-Censits
    Jeannie Hoffman-Censits
  • BMBenjamin Maughan
    Benjamin Maughan
  • TMTina Mayer
    Tina Mayer
  • ATAlan Tan
    Alan Tan
  • RBRachel Brody
    Rachel Brody
  • HXHui Xie
    Hui Xie
  • KNKai Nie
    Kai Nie
  • GKGeoffrey Kelly
    Geoffrey Kelly
  • GIGiorgio Ioannou
    Giorgio Ioannou
  • RCRafael Cabal
    Rafael Cabal

Open Access
Publisher website
Google Scholar
  • 17 July 2026
    • other
    • Published by American Association for Cancer Research (AACR)
    • DOI:10.1158/1078-0432.33014266
Abstract
Figure S4 shows correlation between Olink and overall survival.
Keywords
  • CHEMOTHERAPY
  • COMBINATION CHEMOTHERAPY
  • CLINICAL TRIAL RESULTS
  • PHASE II CLINICAL TRIALS
  • GENITOURINARY CANCERS
  • BLADDER CANCER
  • IMMUNOLOGY
  • IMMUNOMODULATION
  • IMMUNOTHERAPY
  • CHECKPOINT BLOCKADE
Scilit logo

Have questions? Email us at support@scilit.com

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.

MDPI initiatives

  • MDPI Journals
  • MDPI Books
  • Sciforum
  • Proceedings Series
  • Preprints.org
  • SciProfiles
  • Encyclopedia
  • JAMS

Legal

  • Privacy
  • Terms
  • About
  • Contact
  • Disclaimer

Follow us

  • facebook icon
  • x icon
  • linkedin icon

Join us

  • Career

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.